Trial · NCT07553767
Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
NCT07553767, Early phase 1, Not yet recruiting, Ningbo No.2 Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection. Trials, record NCT07553767. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07553767
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
- NCT number
- NCT07553767
- Status
- Not yet recruiting
- Phases
- Early phase 1
- Enrollment
- 156 participants, estimated
- Lead sponsor
- Ningbo No.2 Hospital
- Conditions
- Hepatocellular Carcinoma, HEPATITIS B CHRONIC, Hepatitis B Chronic Infection
- Interventions
- Peginterferon alfa-2b, TDF, TAF, TMF
- First posted
- 2026-04-28
- Last updated
- 2026-04-28
Source ClinicalTrials.gov
Registered outcomes50
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Concentration of Hepatitis B Surface Antigen (Hepatitis B Surface Antigen, HBsAg) | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Serum HBsAg concentration assessed by Chemiluminescent Microparticle Immunoassay (CMIA). Unit: IU/mL |
| Primary | Proportion of patients with HBsAg loss | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Proportion of patients with HBsAg loss (HBsAg \< 0.05 IU/mL) determined by CMIA. Unit: % of patients |
| Primary | Proportion of patients with HBsAg seroconversion | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Proportion of patients with HBsAg loss (HBsAg \< 0.05 IU/mL) and anti-HBs seropositivity (anti-HBs ≥ 10 mIU/mL) determined by CMIA. Unit: % of patients |
| Secondary | Concentration of HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Serum HBV DNA viral load quantified by a TaqMan-based real-time quantitative polymerase chain reaction (qPCR) assay. Unit: IU/mL |
| Secondary | Concentration of Hepatitis B e Antigen (HBeAg) | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Serum HBeAg concentration assessed by CMIA. Unit: S/CO |
| Secondary | Composition and diversity of intestinal microbiota | Baseline, Week 24, Week 48 | Intestinal microbiota analyzed by 16S rRNA gene high-throughput sequencing. Unit: Relative abundance (%) and alpha diversity index |
| Secondary | Recurrence-Free Survival (RFS) | Years 1, 2, 3, 5 | Time to first hepatocellular carcinoma (HCC) recurrence or death from any cause, which is confirmed by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI). Unit: Months |
| Secondary | Overall survival (OS) | Years 1, 2, 3, 5 | Time from enrollment to death from any cause, regardless of the cause of death. Unit: Months |
| Secondary | Concentration of Interleukin-2 (IL-2) | Baseline, Week 24, Week 48 | Serum levels of IL-2 will be measured using cytometric bead array (CBA). Unit: pg/mL |
| Secondary | Concentration of Interleukin-4 (IL-4) | Baseline, Week 24, Week 48 | Serum levels of IL-4 will be measured using cytometric bead array (CBA). Unit: pg/mL |
1 to 10 of 50Source ClinicalTrials.gov
See all 50 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07553767
GET https://conductscience.org/api/trials/v1/NCT07553767/registered?page=2